You are here

Oncology Imaging


"Digistain," which uses invisible mid-infrared light to photograph tissue slices, could help eliminate the human subjectivity and variability in grading cancer tumors, according to research published in Convergent Science Physical Oncology.

T2 weighted-based radiomics proved superior in classification performance than qualitative assessment and diffusion-weighted (DW) imaging for diagnosing pathologic complete response (pCR) in patients with rectal cancer who received therapy prior to their main treatment, according to a March 8 study in Radiology.

One-time prostate-specific antigen (PSA) cancer screenings in men does not improve mortality rates for the disease, according to a study published online March 6 in JAMA.

Zika virus has had a significant impact in North and South America, most notably by causing microcephaly in babies born to infected mothers. But Brazilian researchers have found the deadly virus may be an effective treatment for glioblastoma—the most common and aggressive form of malignant brain tumor in adults.

In patients with early-stage breast cancer, neoadjuvant chemotherapy (NAC) is a common treatment to reduce tumor size before surgery. A team has found dynamic diffuse optical tomography (DDOT) can detect if a tumor has responded to chemotherapy within two weeks of initial treatment—potentially life-saving information for patients. ​​​​​​​


Recent Headlines

Study finds obesity more prevalent in those with history of cancer

New research from Columbia University shows that patients who’ve suffered from cancer may have a harder time warding off extra pounds, and it may be even more difficult for patients of color.

MRI and CT have contributed much to brain tumor care over the years

The prognosis for patients with meningiomas, the most common tumors of the brain and spinal cord, has improved in the decades since advanced imaging began aiding detection. 

Generic version of Gleevec to hit U.S. market

A generic equivalent to Gleevec, imatinib mesylate tablets that treat chronic myeloid leukemia, will now be available in the U.S. for multiple purposes approved by the U.S. Food and Drug Administration.

Research examines how liver cancer could be misclassified

Diagnosing strains of liver cancer can be difficult because they are usually simila, but physicians have various tools to help them. Now, new research at Washington University has found these approaches may not always be accurate.

Lung imaging method helps lower radiotherapy toxicity, study finds

Radiotherapy, a process designed to cure cancer by destroying cancerous tumors, can be harmful to patients if it targets the wrong areas. It is also can be difficult to manage. But new research found a method to perform selective radiotherapy, which can reduce toxicity in the body.

Study: E-cig vapors contain cancer-causing chemicals

Electronic cigarettes contain two previously undiscovered probable carcinogens in their vapor, according to a study in the journal Environmental Science and Technology.

MRI proves a viable contender for prostate screening, but hurdles loom

A pilot study using MRI as the primary screening test for prostate cancer has shown the imaging modality better at predicting the disease than popular—yet controversial—prostate-specific antigen (PSA) blood testing. 

Precision oncology demands fluency in drug toxicity by radiologists

A team of Harvard radiologists is advising fellow rads to bone up on imaging-evident drug toxicity so as to shed their reputation as providers of a standalone service and, more to the point, cement their role as central members of the cancer team in this era of precision oncology. 

Nonsolid lung nodules safely controlled by once-a-year CT scans

Potential lung cancers that show up as nonsolid nodules (NSNs) are innocuous enough that they can be appropriately managed by annual low-dose CT scans in lieu of immediate biopsy or treatment, according to a study published July 5 in Radiology. 

High PSA levels in middle-age men could indicate higher risk for prostate cancer

A new study published in the Journal of Clinical Oncology has found that men who have higher-than-normal prostate-specific antigen (PSA) levels in middle age are more likely to have fatal prostate cancer later in life.